FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3192494915> ?p ?o ?g. }

• W3192494915 endingPage "1265" @default.
• W3192494915 startingPage "1255" @default.
• W3192494915 abstract "BackgroundHeterologous vaccine regimens have been widely discussed as a way to mitigate intermittent supply shortages and to improve immunogenicity and safety of COVID-19 vaccines. We aimed to assess the reactogenicity and immunogenicity of heterologous immunisations with ChAdOx1 nCov-19 (AstraZeneca, Cambridge, UK) and BNT162b2 (Pfizer-BioNtech, Mainz, Germany) compared with homologous BNT162b2 and ChAdOx1 nCov-19 immunisation.MethodsThis is an interim analysis of a prospective observational cohort study enrolling health-care workers in Berlin (Germany) who received either homologous ChAdOx1 nCov-19 or heterologous ChAdOx1 nCov-19–BNT162b2 vaccination with a 10–12-week vaccine interval or homologous BNT162b2 vaccination with a 3-week vaccine interval. We assessed reactogenicity after the first and second vaccination by use of electronic questionnaires on days 1, 3, 5, and 7. Immunogenicity was measured by the presence of SARS-CoV-2-specific antibodies (full spike-IgG, S1-IgG, and RBD-IgG), by an RBD–ACE2 binding inhibition assay (surrogate SARS-CoV-2 virus neutralisation test), a pseudovirus neutralisation assay against two variants of concerns (alpha [B.1.1.7] and beta [B.1.351]), and anti-S1-IgG avidity. T-cell reactivity was measured by IFN-γ release assay.FindingsBetween Dec 27, 2020, and June 14, 2021, 380 participants were enrolled in the study, with 174 receiving homologous BNT162b2 vaccination, 38 receiving homologous ChAdOx1 nCov-19 vaccination, and 104 receiving ChAdOx1 nCov-19–BNT162b2 vaccination. Systemic symptoms were reported by 103 (65%, 95% CI 57·1–71·8) of 159 recipients of homologous BNT162b2, 14 (39%, 24·8–55·1) of 36 recipients of homologous ChAdOx1 nCov-19, and 51 (49%, 39·6–58·5) of 104 recipients of ChAdOx1 nCov-19–BNT162b2 after the booster immunisation. Median anti-RBD IgG levels 3 weeks after boost immunisation were 5·4 signal to cutoff ratio (S/co; IQR 4·8–5·9) in recipients of homologous BNT162b2, 4·9 S/co (4·3–5·6) in recipients of homologous ChAdOx1 nCov-19, and 5·6 S/co (5·1–6·1) in recipients of ChAdOx1 nCov-19– BNT162b2. Geometric mean of 50% inhibitory dose against alpha and beta variants were highest in recipients of ChAdOx1 nCov-19–BNT162b2 (956·6, 95% CI 835·6–1095, against alpha and 417·1, 349·3–498·2, against beta) compared with those in recipients of homologous ChAdOx1 nCov-19 (212·5, 131·2–344·4, against alpha and 48·5, 28·4–82·8, against beta; both p<0·0001) or homologous BNT162b2 (369·2, 310·7–438·6, against alpha and 72·4, 60·5–86·5, against beta; both p<0·0001). SARS-CoV-2 S1 T-cell reactivity 3 weeks after boost immunisation was highest in recipients of ChAdOx1 nCov-19–BNT162b2 (median IFN-γ concentration 4762 mIU/mL, IQR 2723–8403) compared with that in recipients of homologous ChAdOx1 nCov-19 (1061 mIU/mL, 599–2274, p<0·0001) and homologous BNT162b2 (2026 mIU/mL, 1459–4621, p=0·0008) vaccination.InterpretationThe heterologous ChAdOx1 nCov-19–BNT162b2 immunisation with 10–12-week interval, recommended in Germany, is well tolerated and improves immunogenicity compared with homologous ChAdOx1 nCov-19 vaccination with 10–12-week interval and BNT162b2 vaccination with 3-week interval. Heterologous prime-boost immunisation strategies for COVID-19 might be generally applicable.FundingForschungsnetzwerk der Universitätsmedizin zu COVID-19, the German Ministry of Education and Research, Zalando SE." @default.
• W3192494915 created "2021-08-16" @default.
• W3192494915 creator A5000684817 @default.
• W3192494915 creator A5007665606 @default.
• W3192494915 creator A5011184969 @default.
• W3192494915 creator A5011461272 @default.
• W3192494915 creator A5021037707 @default.
• W3192494915 creator A5026117084 @default.
• W3192494915 creator A5038330033 @default.
• W3192494915 creator A5040615109 @default.
• W3192494915 creator A5040973193 @default.
• W3192494915 creator A5041869557 @default.
• W3192494915 creator A5050032617 @default.
• W3192494915 creator A5051717006 @default.
• W3192494915 creator A5054872321 @default.
• W3192494915 creator A5057325351 @default.
• W3192494915 creator A5063085323 @default.
• W3192494915 creator A5066327445 @default.
• W3192494915 creator A5067716705 @default.
• W3192494915 creator A5073782617 @default.
• W3192494915 creator A5074607200 @default.
• W3192494915 creator A5074980216 @default.
• W3192494915 creator A5077556446 @default.
• W3192494915 creator A5084073390 @default.
• W3192494915 creator A5084730856 @default.
• W3192494915 creator A5086835391 @default.
• W3192494915 creator A5091084269 @default.
• W3192494915 date "2021-11-01" @default.
• W3192494915 modified "2023-10-18" @default.
• W3192494915 title "Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study" @default.
• W3192494915 cites W1979742563 @default.
• W3192494915 cites W2106578604 @default.
• W3192494915 cites W3042833857 @default.
• W3192494915 cites W3093367571 @default.
• W3192494915 cites W3099517149 @default.
• W3192494915 cites W3111255098 @default.
• W3192494915 cites W3128949192 @default.
• W3192494915 cites W3131688063 @default.
• W3192494915 cites W3135210768 @default.
• W3192494915 cites W3140226555 @default.
• W3192494915 cites W3141986261 @default.
• W3192494915 cites W3152102956 @default.
• W3192494915 cites W3158483423 @default.
• W3192494915 cites W3160352759 @default.
• W3192494915 cites W3161183609 @default.
• W3192494915 cites W3167899147 @default.
• W3192494915 cites W3175995708 @default.
• W3192494915 cites W4225711802 @default.
• W3192494915 doi "https://doi.org/10.1016/s2213-2600(21)00357-x" @default.
• W3192494915 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8360702" @default.
• W3192494915 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34391547" @default.
• W3192494915 hasPublicationYear "2021" @default.
• W3192494915 type Work @default.
• W3192494915 sameAs 3192494915 @default.
• W3192494915 citedByCount "244" @default.
• W3192494915 countsByYear W31924949152021 @default.
• W3192494915 countsByYear W31924949152022 @default.
• W3192494915 countsByYear W31924949152023 @default.
• W3192494915 crossrefType "journal-article" @default.
• W3192494915 hasAuthorship W3192494915A5000684817 @default.
• W3192494915 hasAuthorship W3192494915A5007665606 @default.
• W3192494915 hasAuthorship W3192494915A5011184969 @default.
• W3192494915 hasAuthorship W3192494915A5011461272 @default.
• W3192494915 hasAuthorship W3192494915A5021037707 @default.
• W3192494915 hasAuthorship W3192494915A5026117084 @default.
• W3192494915 hasAuthorship W3192494915A5038330033 @default.
• W3192494915 hasAuthorship W3192494915A5040615109 @default.
• W3192494915 hasAuthorship W3192494915A5040973193 @default.
• W3192494915 hasAuthorship W3192494915A5041869557 @default.
• W3192494915 hasAuthorship W3192494915A5050032617 @default.
• W3192494915 hasAuthorship W3192494915A5051717006 @default.
• W3192494915 hasAuthorship W3192494915A5054872321 @default.
• W3192494915 hasAuthorship W3192494915A5057325351 @default.
• W3192494915 hasAuthorship W3192494915A5063085323 @default.
• W3192494915 hasAuthorship W3192494915A5066327445 @default.
• W3192494915 hasAuthorship W3192494915A5067716705 @default.
• W3192494915 hasAuthorship W3192494915A5073782617 @default.
• W3192494915 hasAuthorship W3192494915A5074607200 @default.
• W3192494915 hasAuthorship W3192494915A5074980216 @default.
• W3192494915 hasAuthorship W3192494915A5077556446 @default.
• W3192494915 hasAuthorship W3192494915A5084073390 @default.
• W3192494915 hasAuthorship W3192494915A5084730856 @default.
• W3192494915 hasAuthorship W3192494915A5086835391 @default.
• W3192494915 hasAuthorship W3192494915A5091084269 @default.
• W3192494915 hasBestOaLocation W31924949151 @default.
• W3192494915 hasConcept C104317684 @default.
• W3192494915 hasConcept C159047783 @default.
• W3192494915 hasConcept C159654299 @default.
• W3192494915 hasConcept C203014093 @default.
• W3192494915 hasConcept C22070199 @default.
• W3192494915 hasConcept C2777704310 @default.
• W3192494915 hasConcept C2780115692 @default.
• W3192494915 hasConcept C2780868878 @default.
• W3192494915 hasConcept C54355233 @default.
• W3192494915 hasConcept C71924100 @default.
• W3192494915 hasConcept C86803240 @default.
• W3192494915 hasConceptScore W3192494915C104317684 @default.
• W3192494915 hasConceptScore W3192494915C159047783 @default.

• next